OTCMKTS:CYDY CytoDyn Q4 2025 Earnings Results & Report $0.25 +0.01 (+3.64%) As of 12:05 PM Eastern CytoDyn reported Q4 2025 earnings on July 25, 2025. The company reported EPS of -$0.01. Research:ProfileEarnings History Earnings Announcement Details QuarterQ4 2025Report DateJuly 25, 2025TimeAfter Market ClosesConference Call7:00 AM ET CytoDyn EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACytoDyn Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCytoDyn's Q2 2027 earnings is estimated for Thursday, January 14, 2027, based on past reporting schedules, with a conference call scheduled on Friday, January 8, 2027 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) CytoDyn Q4 2025 Earnings FAQ Did CytoDyn beat earnings estimates for Q4 2025? CytoDyn (OTCMKTS:CYDY) reported earnings of -$0.01 per share for Q4 2025. The report was announced on Friday, July 25, 2025. When is CytoDyn's next earnings date? CytoDyn's next earnings date is estimated for Thursday, January 14, 2027. MarketBeat tracks confirmed and estimated earnings dates for CytoDyn on the company's earnings history page. CytoDyn Earnings HeadlinesCytoDyn raises $5M in private placement to support leronlimab programsNovember 12 at 2:45 PM | msn.comCytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid TumorsNovember 12 at 8:30 AM | globenewswire.comUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 13 at 1:00 AM | Digest Publishing (Ad)CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast CancerNovember 10 at 8:30 AM | globenewswire.comCytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026October 26, 2026 | globenewswire.comCytoDyn Announces CEO Transition As Board Appoints Hoffman; Lazaleri Steps DownOctober 20, 2026 | rttnews.comSee More CytoDyn Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CytoDyn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoDyn and other key companies, straight to your email. Email Address About CytoDynCytoDyn (OTCMKTS:CYDY) is a biotechnology company focused on developing leronlimab, an investigational humanized monoclonal antibody that targets the CCR5 receptor. The company is based in Vancouver, Washington. CytoDyn has studied leronlimab in clinical programs involving HIV and cancer, including research into its potential role in treating certain solid tumors. The company’s research has also explored other conditions in which CCR5 may be involved. Leronlimab is an investigational product and is not an approved commercial therapy. CytoDyn’s activities center on its development and clinical research rather than the sale of marketed medicines.View CytoDyn ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
